

Erratum to: Canagliflozin: First Global Approval

Shelley Elkinson · Lesley J. Scott

Published online: 30 October 2013
© Springer International Publishing Switzerland 2013

Erratum to: Drugs (2013) 73:979–988
DOI 10.1007/s40265-013-0064-9

Page 979, column 2, section 1, paragraph 1, lines 9–11:
which previously read:

“pioglitazone), and dipeptidyl peptidase-4 inhibitors (e.g. sitagliptin, saxagliptin, linagliptin), and the injectable meglitinides (e.g. repaglinide, nateglinide), glucagon-like”

should read:

“pioglitazone), dipeptidyl peptidase-4 inhibitors (e.g. sitagliptin, saxagliptin, linagliptin) and meglitinides (e.g. repaglinide, nateglinide), and the injectable glucagon-like”

The online version of the original article can be found under
doi:[10.1007/s40265-013-0064-9](https://doi.org/10.1007/s40265-013-0064-9).

S. Elkinson (✉) · L. J. Scott
Adis R&D Insight, 41 Centorian Drive,
Private Bag 65901, Mairangi Bay, North Shore 0754,
Auckland, New Zealand
e-mail: dru@adis.com